Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of immunogenicity and safety of FluGuard versus Vaxigrip in adults 18–60 years
IRCT20210901052358N5Phase 4Completed
- Sponsor
- Nivad Pharmed Salamat
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of favipiravir in influenza (2 arms), sponsored by Nivad Pharmed Salamat. Primary endpoints: Immunogenicity comparison and Safety comparison. Started Nov 2022; status: completed.
02
Drugs
favipiravir
03
Conditions
influenza
Beyond the preview
Go deeper on IRCT20210901052358N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210901052358N5.